• Vaccine Ontology ID: VO_0011553
• Type: DNA vaccine
• Status: Research
• G gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• Vector: pgp.LAMP-1 (Kaur et al., 2010)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0011555
• Type: Recombinant vector vaccine
• Status: Research
• RABVgp1 nucleoprotein N gene engineering:
  • Type: Recombinant vector construction
  • Detailed Gene Information: Click Here.
• Vector: Vaccinia virus (Fujii et al., 1994)
• Immunization Route: Intraperitoneal injection (i.p.)

• Vaccine Ontology ID: VO_0004372
• Type: DNA vaccine
• Status: Research
• glycoprotein gene engineering:
  • Type: DNA vaccine construction
  • Description: This DNA vaccine expressed the full-length cDNA of the ERA rabies virus glycoprotein (Lodmell et al., 2000).
  • Detailed Gene Information: Click Here.
• Vector: pCMV4 (Lodmell et al., 2000)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0004326
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse
• glycoprotein gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector pSG5 expressed the rabies glycoprotein (ERA strain) (Xiang et al., 1994).
  • Detailed Gene Information: Click Here.
• Vector: pSG5 (Xiang et al., 1994)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0002991
• Type: Live, attenuated vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse, hamster
• Glycoprotein G gene engineering:
  • Type: Gene mutation
  • Description: This glycoprotein G mutant is from Rabies virus (Wu et al., 2011).
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0002992
• Type: Live, attenuated vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse
• P protein gene engineering:
  • Type: Gene mutation
  • Description: This P protein mutant is from rabies virus (Morimoto et al., 2005).
  • Detailed Gene Information: Click Here.
• Immunization Route: Intracranial immunization

Mouse Response

• Vaccination Protocol: For the intramuscular route, mice were vaccinated with 100 µg of endotoxin-free pDNA in 200 µl of PBS/animal in the anterior quadriceps muscle, in the individual groups (DNA vaccine or vector control), 3 times at 3-wk intervals. Control mice were immunized with PBS only (Kaur et al., 2010).
• Challenge Protocol: For challenge studies, immunized mice were inoculated intracerebrally with 20 LD50 of the CVS strain of rabies virus 21 d after the last immunization. The challenged mice were observed for 18 d for symptoms indicative of rabies virus infection (Kaur et al., 2010).
• Efficacy: DNA vaccine imparted partial protection (60%) against challenge with 20 LD(50) of the challenge virus standard (CVS) strain of rabies virus (Kaur et al., 2010).

Mouse Response

• Host Strain: A/J
• Vaccination Protocol: 4-week-old mice were injected intraperitoneally (i.p.) on days 0 and 14 with 10^7 p.f.u, of the recombinant viruses. Control mice received equal doses of vaccinia virus recombinant vSC8 that contained no rabies virus sequences (Fujii et al., 1994).
• Challenge Protocol: On day 21, the mice were challenged by footpad injection with 0.02 ml (20 MFPLDs0 , where MFPLDs0 represents mouse footpad 50% lethal dose) of the 1088 strain (Fujii et al., 1994).
• Efficacy: 92 % of mice given rVac-N (i.e. one animal succumbed b u t still had a prolonged lifespan) survived the challenge with rabies virus (Fujii et al., 1994).

Mouse Response

• Vaccine Immune Response Type: VO_0000286
• Immune Response: Neutralizing antibody titers were enhanced following primary i.m. vaccination with DNA and MPL® (Lodmell et al., 2000).
• Efficacy: After virus challenge, in the group of mice that were vaccinated with MPL, 4 of 6 mice with individual neutralizing antibody titers of 1:10 survived viral challenge. In addition, in the group of mice that did not receive MPL, 100% of the mice survived viral challenge after their second booster (Lodmell et al., 2000).

Mouse Response

• Vaccine Immune Response Type: VO_0000286
• Immune Response: Mice immunized intramuscularly with the pSG5rab.gp vector developed rabies virus glycoprotein-specific cytolytic T cells, lymphokinesecreting T helper cells of the TH1 subset, and rabies virus-neutralizing antibodies (Xiang et al., 1994).
• Efficacy: Mice vaccinated with the pSG5rab.gp vector were fully protected against a subsequent challenge with rabies virus (Xiang et al., 1994).

Mouse Response

• Persistence: A glycoprotein G mutant is attenuated in mice (Wu et al., 2011).
• Efficacy: A glycoprotein G mutant induces protection in mice from challenge with wild type rabies virus (Wu et al., 2011).

Mouse Response

• Persistence: A P protein mutant is attenuated in mice (Morimoto et al., 2005).
• Efficacy: A P protein mutant induces protection in mice from challenge with wild type rabies virus (Morimoto et al., 2005).

Hamster Response

• Persistence: A glycoprotein G mutant is attenuated in hamsters (Wu et al., 2011).
• Efficacy: A glycoprotein G mutant induces significant protection in hamsters from challenge with wild type rabies virus (Wu et al., 2011).